We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Precigen Inc | NASDAQ:PGEN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 6.06% | 1.40 | 1.39 | 1.40 | 1.455 | 1.31 | 1.34 | 683,632 | 21:15:01 |
From May 2021 to May 2024
By Chris Wack
Precigen Inc. said the U.S. Food and Drug Administration has cleared its investigational new drug application to initiate the Phase 1/1b clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive hematological and solid tumors.
The company said its PRGN-3007 is a first-in-class investigational therapy based on the next generation of its UltraCAR-T platform and incorporates intrinsic programmed cell death protein 1 blockade.
This first-in-human study of PRGN-3007 will be conducted in collaboration with the H. Lee Moffitt Cancer Center & Research Institute.
The Phase 1/1b clinical trial is designed to evaluate the safety and efficacy of PRGN-3007 in patients with advanced ROR1(+) hematological and solid tumors.
Precigen shares were up 8% to $4.93 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 26, 2021 08:34 ET (12:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Precigen Chart |
1 Month Precigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
